Show simple item record

dc.contributor.authorBreitborde, Nicholas
dc.contributor.authorMoreno, Francisco
dc.contributor.authorMai-Dixon, Natalie
dc.contributor.authorPeterson, Rachele
dc.contributor.authorDurst, Linda
dc.contributor.authorBernstein, Beth
dc.contributor.authorByreddy, Seenaiah
dc.contributor.authorMcFarlane, William
dc.date.accessioned2016-05-20T08:58:22Z
dc.date.available2016-05-20T08:58:22Z
dc.date.issued2011en
dc.identifier.citationBreitborde et al. BMC Psychiatry 2011, 11:9 http://www.biomedcentral.com/1471-244X/11/9en
dc.identifier.doi10.1186/1471-244X-11-9en
dc.identifier.urihttp://hdl.handle.net/10150/610092
dc.description.abstractBACKGROUND:Multifamily group psychoeducation (MFG) has been shown to reduce relapse rates among individuals with first-episode psychosis. However, given the cognitive demands associated with participating in this intervention (e.g., learning and applying a structured problem-solving activity), the cognitive deficits that accompany psychotic disorders may limit the ability of certain individuals to benefit from this intervention. Thus, the goal of this study is to examine whether individuals with first-episode psychosis who participate simultaneously in MFG and cognitive remediation--an intervention shown to improve cognitive functioning among individuals with psychotic disorders--will be less likely to experience a relapse than individuals who participate in MFG alone.METHODS/DESIGN:Forty individuals with first-episode psychosis and their caregiving relative will be recruited to participate in this study. Individuals with first-episode psychosis will be randomized to one of two conditions: (i) MFG with concurrent participation in cognitive remediation or (ii) MFG alone. The primary outcome for this study is relapse of psychotic symptoms. We will also examine secondary outcomes among both individuals with first-episode psychosis (i.e., social and vocational functioning, health-related quality of life, service utilization, independent living status, and cognitive functioning) and their caregiving relatives (i.e., caregiver burden, anxiety, and depression)DISCUSSION:Cognitive remediation offers the possibility of ameliorating a specific deficit (i.e., deficits in cognitive functioning) that often accompanies psychotic symptoms and may restrict the magnitude of the clinical benefits derived from MFG.TRIAL REGISTRATION:ClinicalTrials (NCT): NCT01196286
dc.language.isoenen
dc.publisherBioMed Centralen
dc.relation.urlhttp://www.biomedcentral.com/1471-244X/11/9en
dc.rights© 2011 Breitborde et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0).en
dc.rights.urihttps://creativecommons.org/licenses/by/2.0/
dc.titleMultifamily Group Psychoeducation and Cognitive Remediation for First-Episode Psychosis: A Randomized Controlled Trialen
dc.typeArticleen
dc.identifier.eissn1471-244Xen
dc.contributor.departmentDepartment of Psychiatry, University of Arizona, 1501 N. Campbell Ave., PO Box 245002, Tucson, AZ, 85724-5002, USAen
dc.contributor.departmentDepartment of Psychiatry, University Physicians Hospital, 2800 E. Ajo Way, Tucson, Arizona, 85713, USAen
dc.contributor.departmentDepartment of Psychiatry, University of Rochester Medical Center, 601 Elmwood Ave., Rochester, New York, 14642, USAen
dc.contributor.departmentDepartment of Psychiatry, Maine Medical Center, 295 Park Ave., Portland, Maine, 04102, USAen
dc.identifier.journalBMC Psychiatryen
dc.description.collectioninformationThis item is part of the UA Faculty Publications collection. For more information this item or other items in the UA Campus Repository, contact the University of Arizona Libraries at repository@u.library.arizona.edu.en
dc.eprint.versionFinal published versionen
refterms.dateFOA2018-09-11T10:46:02Z
html.description.abstractBACKGROUND:Multifamily group psychoeducation (MFG) has been shown to reduce relapse rates among individuals with first-episode psychosis. However, given the cognitive demands associated with participating in this intervention (e.g., learning and applying a structured problem-solving activity), the cognitive deficits that accompany psychotic disorders may limit the ability of certain individuals to benefit from this intervention. Thus, the goal of this study is to examine whether individuals with first-episode psychosis who participate simultaneously in MFG and cognitive remediation--an intervention shown to improve cognitive functioning among individuals with psychotic disorders--will be less likely to experience a relapse than individuals who participate in MFG alone.METHODS/DESIGN:Forty individuals with first-episode psychosis and their caregiving relative will be recruited to participate in this study. Individuals with first-episode psychosis will be randomized to one of two conditions: (i) MFG with concurrent participation in cognitive remediation or (ii) MFG alone. The primary outcome for this study is relapse of psychotic symptoms. We will also examine secondary outcomes among both individuals with first-episode psychosis (i.e., social and vocational functioning, health-related quality of life, service utilization, independent living status, and cognitive functioning) and their caregiving relatives (i.e., caregiver burden, anxiety, and depression)DISCUSSION:Cognitive remediation offers the possibility of ameliorating a specific deficit (i.e., deficits in cognitive functioning) that often accompanies psychotic symptoms and may restrict the magnitude of the clinical benefits derived from MFG.TRIAL REGISTRATION:ClinicalTrials (NCT): NCT01196286


Files in this item

Thumbnail
Name:
1471-244X-11-9.pdf
Size:
245.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

© 2011 Breitborde et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0).
Except where otherwise noted, this item's license is described as © 2011 Breitborde et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0).